DK3675853T3 - Fremgangsmåder til forbedring og/eller stabilisering af hjertefunktionen hos patienter med fabrys sygdom - Google Patents

Fremgangsmåder til forbedring og/eller stabilisering af hjertefunktionen hos patienter med fabrys sygdom Download PDF

Info

Publication number
DK3675853T3
DK3675853T3 DK18766482.6T DK18766482T DK3675853T3 DK 3675853 T3 DK3675853 T3 DK 3675853T3 DK 18766482 T DK18766482 T DK 18766482T DK 3675853 T3 DK3675853 T3 DK 3675853T3
Authority
DK
Denmark
Prior art keywords
fabry
patients
disease
improving
methods
Prior art date
Application number
DK18766482.6T
Other languages
English (en)
Inventor
Jeff Castelli
Jay Barth
Nina Skuban
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63528948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3675853(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Application granted granted Critical
Publication of DK3675853T3 publication Critical patent/DK3675853T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK18766482.6T 2017-08-28 2018-08-28 Fremgangsmåder til forbedring og/eller stabilisering af hjertefunktionen hos patienter med fabrys sygdom DK3675853T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762550984P 2017-08-28 2017-08-28
PCT/US2018/048257 WO2019046244A1 (en) 2017-08-28 2018-08-28 METHODS FOR ENHANCING AND / OR STABILIZING CARDIAC FUNCTION IN PATIENTS WITH FABRY DISEASE

Publications (1)

Publication Number Publication Date
DK3675853T3 true DK3675853T3 (da) 2022-11-28

Family

ID=63528948

Family Applications (2)

Application Number Title Priority Date Filing Date
DK22194251.9T DK4176877T3 (da) 2017-08-28 2018-08-28 Fremgangsmåder til forbedring og/eller stabilisering af hjertefunktionen hos patienter med fabrys sygdom
DK18766482.6T DK3675853T3 (da) 2017-08-28 2018-08-28 Fremgangsmåder til forbedring og/eller stabilisering af hjertefunktionen hos patienter med fabrys sygdom

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK22194251.9T DK4176877T3 (da) 2017-08-28 2018-08-28 Fremgangsmåder til forbedring og/eller stabilisering af hjertefunktionen hos patienter med fabrys sygdom

Country Status (26)

Country Link
US (1) US20200222377A1 (da)
EP (3) EP4588476A1 (da)
JP (3) JP7755929B2 (da)
KR (2) KR102790184B1 (da)
CN (1) CN111770753A (da)
AR (1) AR112482A1 (da)
AU (2) AU2018326364B2 (da)
CA (1) CA3074450C (da)
CL (1) CL2020000491A1 (da)
DK (2) DK4176877T3 (da)
EA (1) EA202090564A1 (da)
ES (2) ES3013820T3 (da)
FI (1) FI4176877T3 (da)
HR (2) HRP20250064T1 (da)
HU (2) HUE060287T2 (da)
IL (3) IL310648A (da)
LT (2) LT4176877T (da)
MX (2) MX2020002229A (da)
PL (2) PL3675853T3 (da)
PT (2) PT3675853T (da)
RS (2) RS63742B1 (da)
SG (1) SG11202001707PA (da)
SI (1) SI4176877T1 (da)
SM (2) SMT202500073T1 (da)
TW (1) TWI845479B (da)
WO (1) WO2019046244A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009537149A (ja) 2006-05-16 2009-10-29 アミークス セラピューティックス インコーポレイテッド ファブリー病に対する治療の選択を診断し、評価するためのアッセイ
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
KR20220116305A (ko) 2017-05-30 2022-08-22 아미쿠스 세라퓨틱스, 인코포레이티드 신장 손상을 갖는 파브리 환자를 치료하는 방법
PT3675853T (pt) 2017-08-28 2022-11-28 Amicus Therapeutics Inc Métodos para melhorar e/ou estabilizar a função cardíaca em pacientes com doença de fabry
EP3749307B1 (en) 2018-02-06 2025-12-10 Amicus Therapeutics, Inc. Use of migalastat for treating fabry disease in pregnant patients
EP4289476A3 (en) 2018-08-20 2024-02-21 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
WO2021026447A1 (en) * 2019-08-07 2021-02-11 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
TR2024011149A1 (tr) 2024-08-23 2026-03-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Mi̇galastat i̇çeren kapsül formülasyonlari
CN119120696A (zh) * 2024-11-12 2024-12-13 北京贝瑞和康生物技术有限公司 检测法布雷病gla基因突变的引物组、试剂盒及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
MX2009010557A (es) 2007-03-30 2009-11-19 Amicus Therapeutics Inc Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
PT3675853T (pt) 2017-08-28 2022-11-28 Amicus Therapeutics Inc Métodos para melhorar e/ou estabilizar a função cardíaca em pacientes com doença de fabry
US10811814B2 (en) 2017-08-28 2020-10-20 John Mezzalingua Associates, LLC Weather protecting (WP) housing for coaxial cable connectors

Also Published As

Publication number Publication date
SG11202001707PA (en) 2020-03-30
AU2024266945A1 (en) 2024-12-19
PL4176877T3 (pl) 2025-04-07
CA3074450A1 (en) 2019-03-07
FI4176877T3 (fi) 2025-03-06
KR20200044908A (ko) 2020-04-29
DK4176877T3 (da) 2025-02-24
JP2023051998A (ja) 2023-04-11
HRP20221366T1 (hr) 2023-01-06
JP2025138638A (ja) 2025-09-25
RS66515B1 (sr) 2025-03-31
KR102790184B1 (ko) 2025-04-01
US20200222377A1 (en) 2020-07-16
LT4176877T (lt) 2025-02-10
JP7755929B2 (ja) 2025-10-17
CN111770753A (zh) 2020-10-13
IL310648A (en) 2024-04-01
AU2018326364B2 (en) 2024-08-29
IL272893B2 (en) 2024-07-01
IL272893A (en) 2020-04-30
TW201919619A (zh) 2019-06-01
HRP20250064T1 (hr) 2025-03-14
EP3675853B1 (en) 2022-09-07
JP2020531550A (ja) 2020-11-05
MX2020002229A (es) 2020-07-20
EA202090564A1 (ru) 2020-06-15
PT4176877T (pt) 2025-02-24
HUE060287T2 (hu) 2023-02-28
PL3675853T3 (pl) 2022-12-27
IL324182A (en) 2025-12-01
EP4176877A1 (en) 2023-05-10
AU2018326364A1 (en) 2020-04-09
AR112482A1 (es) 2019-10-30
LT3675853T (lt) 2022-12-12
SMT202200459T1 (it) 2023-01-13
ES3013820T3 (en) 2025-04-15
IL272893B1 (en) 2024-03-01
CA3074450C (en) 2024-10-01
BR112020003974A2 (pt) 2020-09-01
ES2931054T3 (es) 2022-12-23
EP3675853A1 (en) 2020-07-08
EP4176877B1 (en) 2024-12-04
WO2019046244A1 (en) 2019-03-07
KR20250049561A (ko) 2025-04-11
PT3675853T (pt) 2022-11-28
RS63742B1 (sr) 2022-12-30
EP4588476A1 (en) 2025-07-23
SI4176877T1 (sl) 2025-03-31
TWI845479B (zh) 2024-06-21
CL2020000491A1 (es) 2020-09-11
MX2023005628A (es) 2023-05-24
SMT202500073T1 (it) 2025-03-12
HUE070433T2 (hu) 2025-06-28

Similar Documents

Publication Publication Date Title
DK4176877T3 (da) Fremgangsmåder til forbedring og/eller stabilisering af hjertefunktionen hos patienter med fabrys sygdom
IL280483A (en) Muscle targeting complexes and uses thereof for treating pompe disease
IL280566A (en) Systems and methods for affecting cardiac contractility and/or relaxation
EP3694529A4 (en) TRISPECIFIC PROTEINS AND METHOD OF USE
IL255119B (en) Therapeutic pooled blood apoptotic cell preparations and uses thereof
DK3676285T3 (da) Vaccine til anvendelse i profylakse og/eller behandling af en sygdom
PT3681857T (pt) Fluorofenil-beta-hidroxietilaminas e sua utilização no tratamento de hiperglicemia
DK3377637T3 (da) Sammensætninger til anvendelse i fremgangsmåder til behandling af sår, lidelser og sygdomme i huden
DK4000662T3 (da) Kunstigt lungesystem og anvendelsesfremgangsmåder, der ikke udføres på den levende menneske- eller dyrekrop
DK3526207T3 (da) Heterocykliske forbindelser med aktivitet som modulatorer af muscarine m1- og/eller m4-receptorer i behandling af cns-sygdomme og smerter
DK3830119T3 (da) Anti-btn3a-antistoffer og deres anvendelse til behandling af kræft eller infektionssygdomme
EP3376977A4 (en) RECOVERY AND PROCESSING OF HUMAN EMBRYOS MADE IN VIVO
EP3681862C0 (en) BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCEMIA
IL284414A (en) Methods and compositions for the treatment of fabry disease
DK3749308T3 (da) Behandling af patienter med klassisk fabrys sygdom med migalastat
DK3570739T3 (da) Indretninger og fremgangsmåder til at bestemme hjertefunktionen hos en levende person
DK3387019T3 (da) Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder
SG11202000423XA (en) Treatment of fabry disease in ert-naïve and ert-experienced patients
IL283916A (en) Antibodies to human complement factor c2b and methods of use
DK3882629T3 (da) Overvågning af mykotoksiner og deres metabolitter i blodet hos svin eller slagtekyllinger
DK3746469T3 (da) Antikoagulerende proteiner og deres anvendelse til behandling af sygdomme associeret med aktiveringen af neutrofiler
EP3814326A4 (en) DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS INDUCED DISEASES
ITUA20163417A1 (it) Fat and medical uses thereof
EP3703820A4 (en) USE OF MIR101 OR MIR128 IN THE TREATMENT OF EPILEPTIC DISORDERS
DK3448430T3 (da) Anvendelse af en acetylcholinesterase-inhibitor og idalopirdin til reduktion af fald hos patienter med parkinsons sygdom